Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for treating amyloidosis

a technology for amyloidosis and amyloidosis, which is applied in the field of amyloidosis treatment, can solve the problems of no known treatment or therapy which significantly dissolves the deposits in situ, and achieves the effect of slowing down the absorption of active compounds

Inactive Publication Date: 2003-06-12
NEUROCHEM INT
View PDF0 Cites 38 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Once these amyloids have formed, there is no known therapy or treatment which significantly dissolves the deposits in situ which is widely accepted.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating amyloidosis
  • Method for treating amyloidosis
  • Method for treating amyloidosis

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0085] The following methodologies were used:

[0086] Animals

[0087] All mice were of the CD strain (Charles Rivers, Montreal, Quebec) and weighing 25-30 g.

[0088] Animal Treatment

[0089] All animals received AgNO.sub.3 (0.5 ml, 2% solution) subcutaneously in the back, and amyloid enhancing factor (AEF) 100 .mu.g intravenously. The preparation of amyloid enhancing factor has been described previously in Axelrad, M. A. et al. ("Further Characterization of Amyloid Enhancing Factor" Lab. Invest. 47:139-146 (1982)). The animals were divided into several groups one of which was an untreated control group which was sacrificed six days later. The remaining animals were divided into those which received poly(vinylsulfonate sodium salt) (PVS) at 50 mg, 40 mg, 20 mg, or 10 mg by intraperitoneal injection every 12 hours or sucrose octasulfate ammonium salt (SOA) at 73 mg or 36.5 mg every 8 hours by IP injection. The PVS used in this and all subsequent Examples was a mixture of stereoisomers. Surviv...

example 2

[0099] Swiss white mice weighing 25-30 g were given Amyloid Enhancing Factor (AEF) and AgNO.sub.3 as described previously (Kisilevsky, R. and Boudreau, L. (1983) "The kinetics of amyloid deposition: I. The effect of amyloid enhancing factor and splenectomy" Lab. Invest., 48, 53-59), to induce amyloidosis. Twenty four (24) hours later they were divided into three groups. One group served as a control and was maintained on standard laboratory mouse chow and tap water ad lib. A second group received the standard chow but its water contained 20 mg / ml of poly(vinylsulfonate sodium salt) (PVS). The third group had 50 mg / ml of PVS in its drinking water. Fluid intake in both groups was the same. All animals were sacrificed on day six (6) of the experiment, their spleens collected, prepared for sectioning, spleen sections stained with Congo red (Puchtler, H., et al. (1983) "Application of Thiazole Dyes to Amyloid under Conditions of Direct Cotton Dyeing: Correlation of Histochemical and Chem...

example 3

[0100] Since it was possible that PVS was inhibiting the hepatic synthesis of the amyloid precursor, and thus failure to deposit amyloid was due to the absence of the precursor pool, the effect of PVS on the blood level of the amyloid precursor (SAA) during the course of the experiment was determined. Animals received AEF+AgNO.sub.3 as described above and were divided into two groups. Group I received no further treatment. Twenty four hours later, Group 2 received 50 mg of PVS by intraperitoneal injection every 12 hours for a period of 5 days. To plot the level of SAA during this process, each animal (controls and experimentals) was bled from the tail (.apprxeq.25 .mu.l) each day. The SAA levels in these samples were determined by a solid phase ELISA procedure (described in Brissette, L., et al. (1989) J. Biol. Chem., 264, 19327-19332). The results are shown in FIG. 5. The open circles represent the data from the PVS-treated mice, while the triangles show the data from the non-treat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
pHaaaaaaaaaa
concentrationsaaaaaaaaaa
Login to View More

Abstract

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

Description

[0001] This application is a continuation-in-part of application Ser. No. 08 / 403,230, filed Mar. 15, 1995, which is a continuation-in-part of application Ser. No. 08 / 315,391, filed Sep. 29, 1994, which is a continuation-in-part of application Ser. No. 08 / 219,798, filed Mar. 29, 1994, which is a continuation-in-part of application Ser. No. 08 / 037,844 filed Mar. 29, 1993, now abandoned, the contents of all of which are incorporated herein by reference.BACKGROUND OF INVENTION[0002] Amyloidosis refers to a pathological condition characterized by the presence of amyloid. Amyloid is a generic term referring to a group of diverse but specific extracellular protein deposits which are seen in a number of different diseases. Though diverse in their occurrence, all amyloid deposits have common morphologic properties, stain with specific dyes (e.g., Congo red), and have a characteristic red-green birefringent appearance in polarized light after staining. They also share common ultrastructural f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/185A61K31/255A61K31/41A61K31/70A61K31/737A61K31/795A61K47/48A61L33/08C07H11/00C07H15/04
CPCA61K31/185C07H15/04A61K31/41A61K31/70A61K31/737A61K31/795A61K47/48007A61K47/48023A61K47/48092A61K47/481A61K47/4813A61K47/48176A61L33/08C07H11/00A61K31/255A61K47/51A61K47/54A61K47/549A61K47/55A61K47/555A61K47/58
Inventor KISILEVSKY, ROBERTSZAREK, WALTERWEAVER, DONALD
Owner NEUROCHEM INT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com